Skip to main content
. 2019 Dec 18;12(1):4. doi: 10.3390/cancers12010004

Figure 3.

Figure 3

Summary of molecular design of mitochondria-targeted conventional drugs. (A) Mitochondria-targeted doxorubicin, (B) mitochondria-targeted glycyrrhetinic acid, (C) mitochondria-targeted chlorambucil, and (D) mitochondria-targeted pro-DLC.